BridgeMD
New treatment option for Ureteropelvic Junction Obstruction
Official title CTT on Renogram as an Early Marker of Significant Obstruction in Uretero-pelvic Junction Syndrome
ClinicalTrials.gov ID: NCT02812212
What this study is testing
- What it's testing
- Cortical transit time on diuretic renogram as an early marker of significant obstruction in antenatally detected uretero-pelvic junction syndrome
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 4 to 8
You may be able to join if
- Infants:
- Aged of 4 to 8 weeks of life
- Presenting an ureteropelvic junction obstruction (UPJO) detected before birth by ultrasound
- Presenting an UPJO, defined by an Antero-Posterior Renal Pelvic Diameter greater or equal to 15 mm, confirmed by ultrasound post-natally between the...
- Presenting a unilateral UPJO
You likely can't join if
- Infants presenting:
- A bilateral UPJO
- An ureteral dilatation
- An associated contralateral uropathy
- A solitary kidney
- A renal insufficiency
See the full eligibility criteria
- Infants:
- Aged of 4 to 8 weeks of life
- Presenting an ureteropelvic junction obstruction (UPJO) detected before birth by ultrasound
- Presenting an UPJO, defined by an Antero-Posterior Renal Pelvic Diameter greater or equal to 15 mm, confirmed by ultrasound post-natally between the 1st and 15th day of life
- Presenting a unilateral UPJO
- whose legal representatives have provided a signed free and informed written consent for their infant's participation
- whose at least one of his legal representative is affiliated to national social security
- Infants presenting:
- A bilateral UPJO
- An ureteral dilatation
- An associated contralateral uropathy
- A solitary kidney
- A renal insufficiency
- Severe associated disabilities ( ie polymalformation syndromes)
- A concomitant participation in another trial
- A contraindication to furosemide (acute renal insufficiency, hepatic encephalopathy, hypovolemia or dehydration, severe hypokalemia, severe hyponatremia)
- A contraindication to the radionuclide marker (hypersensitivity to the active substance or to excipients)
The study team makes the final eligibility decision.
Where it's taking place
- Bordeaux, France
- Limoges, France
- Nantes, France
- Rennes, France
- Saint-Denis, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 4 weeks to 8 weeks. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Bordeaux, France; Limoges, France; Nantes, France; Rennes, France; Saint-Denis, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.